Inozyme Pharma Inc Ordinary Shares INZY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting
-
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
-
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
-
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
-
Inozyme Pharma Gets FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
-
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
Trading Information
- Previous Close Price
- $5.14
- Day Range
- $5.12–5.29
- 52-Week Range
- $2.69–7.80
- Bid/Ask
- $4.38 / $6.90
- Market Cap
- $347.57 Mil
- Volume/Avg
- 103,896 / 282,056
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 59
- Website
- https://www.inozyme.com
Comparables
Valuation
|
Metric
|
INZY
|
TSHA
|
TVTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 53.09 | — |
Price/Book Value | 3.41 | 3.83 | 70.72 |
Price/Sales | — | 32.20 | 6.06 |
Price/Cash Flow | — | — | — |
Price/Earnings
INZY
TSHA
TVTX
Financial Strength
|
Metric
|
INZY
|
TSHA
|
TVTX
|
|---|---|---|---|
Quick Ratio | 9.30 | 5.05 | 2.89 |
Current Ratio | 9.84 | 5.22 | 3.04 |
Interest Coverage | — | −52.79 | −35.20 |
Quick Ratio
INZY
TSHA
TVTX
Profitability
|
Metric
|
INZY
|
TSHA
|
TVTX
|
|---|---|---|---|
Return on Assets (Normalized) | −45.71% | −40.83% | −9.03% |
Return on Equity (Normalized) | −65.67% | −216.63% | −47.00% |
Return on Invested Capital (Normalized) | −51.78% | −77.31% | −13.68% |
Return on Assets
INZY
TSHA
TVTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Bywxkhqqb | Wsxq | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Khswwpp | Dthbs | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yfylchw | Nwsmpt | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Khywsyhl | Rmtpxp | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Kpzdcsphm | Vsf | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Wxntxwm | Trhpq | $28.1 Bil | |||
| Moderna Inc
MRNA
| Pppsrxcz | Bkyq | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Sccpccjwy | Bcxmn | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jcpwzdmb | Ffxbp | $13.4 Bil | |||
| Incyte Corp
INCY
| Jltfwwtm | Kvnxsyz | $12.7 Bil |
United States